Pipeline

Antabio portfolio

ANTABIO has developed a portfolio of first- or best-in-class antibacterial programs to address high unmet medical, targeting WHO and CDC critical priority pathogens, such as Carbapenem-Resistant Acinetobacter baumannii (CRAB), Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) and Carbapenem-Resistant Enterobacterales (CRE).

Menu